Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631065 | 0.81 | TRPM5 (0.39) | TRPM5 | |
| SCHEMBL910839 | 0.69 | KDM4E (0.39) | TRPM5NSD2CASP6LMNAL3MBTL1 | |
| SCHEMBL5439074 | 0.69 | CYP3A4 (0.39) | TRPM5LMNASMN1; SMN2 | |
| SCHEMBL8071753 | 0.69 | TRPM5 (0.39) | TRPM5LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL12603990 | 0.69 | CA2 (0.39) | TRPM5GABRA1GABRB2 | |
| SCHEMBL13913279 | 0.69 | GABRA1 (0.39) | TRPM5GABRA1GABRB2LMNA | |
| SCHEMBL2610672 | 0.68 | CYP2A6 (0.50) | GABRA1GABRB2KCNH2SCN5ACACNA1C | |
| SCHEMBL29696556 | 0.67 | PLK4 (0.47) | TRPM5 | |
| SCHEMBL11382202 | 0.65 | ALDH1A1 (0.46) | TRPM5LMNASMN1; SMN2 | |
| SCHEMBL30129737 | 0.65 | ALDH1A1 (0.46) | TRPM5LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| WO-2016012333-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | TRPM5 3367/4885GABRA1 3287/4885GABRB2 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.